Covidien Pure-Play: Pharma Spin-Off Now Officially In The Works
This article was originally published in The Pink Sheet Daily
Executive Summary
Covidien says it has been working for several years towards separating out its pharma business from its larger and more profitable devices/supplies division.
You may also be interested in...
Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch
With Nuvo’s new Pennsaid 2% formulation hung up at FDA, Apotex may be able to launch its generic of the old 1.5% formulation of the topical diclofenac product on April 1, 2014, under a settlement announced in January.
Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch
With Nuvo’s new Pennsaid 2% formulation hung up at FDA, Apotex may be able to launch its generic of the old 1.5% formulation of the topical diclofenac product on April 1, 2014, under a settlement announced in January.
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.